SG/CALL/AMGEN/380/0.1/21.06.24 Stock

DE000SU6V4H0

Market Closed - Boerse Frankfurt Warrants 04:01:37 2024-06-14 am EDT
0.001 ^EUR	0.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto	Jun. 14	DJ
Amgen : Continues to Propel BiTE® Technology Innovation	Jun. 14	PU
Amgen Says FDA Approves Blincyto to Treat Type of Blood Cancer	Jun. 14	MT
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE	Jun. 14	PR

More news

Quotes 5-day view

Date	Price	Change
24-06-14	0.001	0.00%
24-06-13	0.001	0.00%
24-06-12	0.001	0.00%
24-06-11	0.001	0.00%
24-06-10	0.001	0.00%

Real-time Boerse Frankfurt Warrants

Last update June 14, 2024 at 04:01 am EDT

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	Société Générale
WKN	SU6V4H
ISIN	DE000SU6V4H0
Date issued	2024-01-10
Strike	380 $
Maturity	2024-06-21 (5 Days)
Parity	10 : 1
Emission price	0.31 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.44 €
Lowest since issue	0.001 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	0x
Moneyness	0.7855
Difference Strike	81.38 $
Difference Strike %	+21.42%
Intrinsic value	0.000000

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company